Tissue Engineering And Nanotheranostics

(Steven Felgate) #1

“9.61x6.69” b2815 Tissue Engineering and Nanotheranostics


Magnetic Nanohybrids for Magnetic Resonance Imaging 103

therapeutic drugs simultaneously with same dose for improved treat-


ment. Better molecular understanding is very important to synthesize


novel efficient targeted therapy agents and optimize drug selection.^7


Moreover, theranostics endeavors to observe the treatment response,


to boost drug efficacy with safety, and to remove the redundant treat-


ment of patients. As a result, theranostic proves to be cost effective


for the overall healthcare system. Hence, the promising science of


theranostics appears to present a distinctive opportunity to diagnos-


tics and pharmaceutical companies to fulfill the regulatory and finan-


cial restrictions imposed by the Food and Drug Administrations


(FDA).8,9 Earlier theranostics, imaging contrast agents were simply


mixed to the delivery vehicles loaded with therapy carriers for use in


magnetic resonance imaging (MRI), positron emission tomography


(PET) and computed tomography (CT). Therefore, the foremost


objective of the theranostic research area is to attain the capability to


monitor the diseased tissue, drug efficiency, imaging, delivery kinet-


ics, and tune the therapy and dose rate in a controlled manner based


on the requirements.^10


The appearance of nanotechnology has provided the opportunity


and made it easier to bring diagnosis and therapy factors closer.


Nanostructured materials are assumed to be the fundamental building


blocks of practical nanotechnology and thus can be manipulated for


Fig. 1. Main interactions between fields of nanotechnology and biology, Redrawn
from Roco (2003), from Ref. 5.^

Free download pdf